Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: A randomized controlled trial

Daisuke Murakami, Motohiro Sawatsubashi, Hirofumi Omori, Akira Saito, Akio Kato, Shizuo Komune, Takashi Nakagawa

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Current allergen-specific immunotherapy (AIT) for pollinosis requires long-term treatment with potentially severe side effects. Therefore, development of an AIT that is safe and more convenient with a shorter regimen is needed. This prospective, double-blind, placebo-controlled trial randomized 55 participants with Japanese cedar pollinosis (JCP) to active or placebo groups to test the safety and efficacy of short-term oral immunotherapy (OIT) with Cry j 1-galactomannan conjugate for JCP. Mean symptom-medication score as the primary outcome in the active group improved 27.8% relative to the placebo group during the entire pollen season. As the secondary outcomes, mean medication score in active group improved significantly, by 56.2%, compared with placebo during the entire pollen season. Mean total symptom score was similar between active and placebo groups during the entire pollen season. There were no severe treatment-emergent adverse events in the active and placebo groups. Therefore short-term OIT with Cry j 1-galactomannan conjugate is safe, and effective for reducing the amount of medication use for JCP.

元の言語英語
記事番号46142
ジャーナルScientific reports
7
DOI
出版物ステータス出版済み - 4 11 2017

Fingerprint

Cryptomeria
Seasonal Allergic Rhinitis
Immunotherapy
Randomized Controlled Trials
Placebos
Safety
Pollen
Immunologic Desensitization
galactomannan
Therapeutics

All Science Journal Classification (ASJC) codes

  • General

これを引用

Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis : A randomized controlled trial. / Murakami, Daisuke; Sawatsubashi, Motohiro; Omori, Hirofumi; Saito, Akira; Kato, Akio; Komune, Shizuo; Nakagawa, Takashi.

:: Scientific reports, 巻 7, 46142, 11.04.2017.

研究成果: ジャーナルへの寄稿記事

@article{38b751a35f8149aca8909b53916e6e74,
title = "Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: A randomized controlled trial",
abstract = "Current allergen-specific immunotherapy (AIT) for pollinosis requires long-term treatment with potentially severe side effects. Therefore, development of an AIT that is safe and more convenient with a shorter regimen is needed. This prospective, double-blind, placebo-controlled trial randomized 55 participants with Japanese cedar pollinosis (JCP) to active or placebo groups to test the safety and efficacy of short-term oral immunotherapy (OIT) with Cry j 1-galactomannan conjugate for JCP. Mean symptom-medication score as the primary outcome in the active group improved 27.8{\%} relative to the placebo group during the entire pollen season. As the secondary outcomes, mean medication score in active group improved significantly, by 56.2{\%}, compared with placebo during the entire pollen season. Mean total symptom score was similar between active and placebo groups during the entire pollen season. There were no severe treatment-emergent adverse events in the active and placebo groups. Therefore short-term OIT with Cry j 1-galactomannan conjugate is safe, and effective for reducing the amount of medication use for JCP.",
author = "Daisuke Murakami and Motohiro Sawatsubashi and Hirofumi Omori and Akira Saito and Akio Kato and Shizuo Komune and Takashi Nakagawa",
year = "2017",
month = "4",
day = "11",
doi = "10.1038/srep46142",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis

T2 - A randomized controlled trial

AU - Murakami, Daisuke

AU - Sawatsubashi, Motohiro

AU - Omori, Hirofumi

AU - Saito, Akira

AU - Kato, Akio

AU - Komune, Shizuo

AU - Nakagawa, Takashi

PY - 2017/4/11

Y1 - 2017/4/11

N2 - Current allergen-specific immunotherapy (AIT) for pollinosis requires long-term treatment with potentially severe side effects. Therefore, development of an AIT that is safe and more convenient with a shorter regimen is needed. This prospective, double-blind, placebo-controlled trial randomized 55 participants with Japanese cedar pollinosis (JCP) to active or placebo groups to test the safety and efficacy of short-term oral immunotherapy (OIT) with Cry j 1-galactomannan conjugate for JCP. Mean symptom-medication score as the primary outcome in the active group improved 27.8% relative to the placebo group during the entire pollen season. As the secondary outcomes, mean medication score in active group improved significantly, by 56.2%, compared with placebo during the entire pollen season. Mean total symptom score was similar between active and placebo groups during the entire pollen season. There were no severe treatment-emergent adverse events in the active and placebo groups. Therefore short-term OIT with Cry j 1-galactomannan conjugate is safe, and effective for reducing the amount of medication use for JCP.

AB - Current allergen-specific immunotherapy (AIT) for pollinosis requires long-term treatment with potentially severe side effects. Therefore, development of an AIT that is safe and more convenient with a shorter regimen is needed. This prospective, double-blind, placebo-controlled trial randomized 55 participants with Japanese cedar pollinosis (JCP) to active or placebo groups to test the safety and efficacy of short-term oral immunotherapy (OIT) with Cry j 1-galactomannan conjugate for JCP. Mean symptom-medication score as the primary outcome in the active group improved 27.8% relative to the placebo group during the entire pollen season. As the secondary outcomes, mean medication score in active group improved significantly, by 56.2%, compared with placebo during the entire pollen season. Mean total symptom score was similar between active and placebo groups during the entire pollen season. There were no severe treatment-emergent adverse events in the active and placebo groups. Therefore short-term OIT with Cry j 1-galactomannan conjugate is safe, and effective for reducing the amount of medication use for JCP.

UR - http://www.scopus.com/inward/record.url?scp=85017359880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017359880&partnerID=8YFLogxK

U2 - 10.1038/srep46142

DO - 10.1038/srep46142

M3 - Article

C2 - 28397833

AN - SCOPUS:85017359880

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 46142

ER -